{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+Part+A&page=2",
    "query": {
      "intervention": "Placebo- Part A",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+Part+A&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-18T21:55:33.940Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02289495",
      "title": "A Repeat Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "GSK2838232",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Ritonavir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 24,
      "start_date": "2014-11-18",
      "completion_date": "2015-06-27",
      "has_results": false,
      "last_update_posted_date": "2017-05-09",
      "last_synced_at": "2026-09-18T21:55:33.940Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02289495"
    },
    {
      "nct_id": "NCT06702449",
      "title": "A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Urinary Tract Infections"
      ],
      "interventions": [
        {
          "name": "Candidate UTI vaccine low dose formulation 1",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Candidate UTI vaccine low dose formulation 2",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Candidate UTI vaccine medium dose formulation 1",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Candidate UTI vaccine medium dose formulation 2",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Candidate UTI vaccine high dose formulation 1",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Candidate UTI vaccine high dose formulation 2",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Candidate UTI vaccine HTD formulation 2",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 448,
      "start_date": "2024-11-19",
      "completion_date": "2027-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-21",
      "last_synced_at": "2026-09-18T21:55:33.940Z",
      "location_count": 6,
      "location_summary": "Lenexa, Kansas • Secaucus, New Jersey • Rochester, New York + 3 more",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Secaucus",
          "state": "New Jersey"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Weatherford",
          "state": "Texas"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06702449"
    },
    {
      "nct_id": "NCT04589611",
      "title": "Translating Metabolic Responses to Mechanical Insult Into Early Interventions to Prevent PTOA",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Osteoarthritis",
        "Post-traumatic Osteoarthritis"
      ],
      "interventions": [
        {
          "name": "amobarbital/Gel-One (one dose)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (single dose)",
          "type": "DRUG"
        },
        {
          "name": "amobarbital/Gel-One (two doses)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (two doses)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "J L Marsh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 5,
      "start_date": "2022-07-20",
      "completion_date": "2025-05-01",
      "has_results": true,
      "last_update_posted_date": "2026-07-06",
      "last_synced_at": "2026-09-18T21:55:33.940Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04589611"
    },
    {
      "nct_id": "NCT04789148",
      "title": "Effects of Intranasal Oxytocin in Patients With Arginine-vasopressin Deficiency",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Vasopressin Deficiency"
      ],
      "interventions": [
        {
          "name": "Intranasal Oxytocin (IN-OXT)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Elizabeth Austen Lawson",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2025-09-10",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-07-23",
      "last_synced_at": "2026-09-18T21:55:33.940Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04789148"
    },
    {
      "nct_id": "NCT01674036",
      "title": "Safety, Tolerability and Pharmacokinetics of Genz-682452 in Healthy Men",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteer"
      ],
      "interventions": [
        {
          "name": "Genz-682452",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "MALE",
        "summary": "18 Years to 45 Years · Male only"
      },
      "enrollment_count": 63,
      "start_date": "2012-08",
      "completion_date": "2013-01",
      "has_results": false,
      "last_update_posted_date": "2014-03-19",
      "last_synced_at": "2026-09-18T21:55:33.940Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01674036"
    },
    {
      "nct_id": "NCT04103892",
      "title": "A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adjunctive Treatment of Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "CLE-100",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Clexio Biosciences Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 146,
      "start_date": "2019-09-05",
      "completion_date": "2022-10-05",
      "has_results": true,
      "last_update_posted_date": "2025-10-14",
      "last_synced_at": "2026-09-18T21:55:33.940Z",
      "location_count": 45,
      "location_summary": "Bentonville, Arkansas • Little Rock, Arkansas • Anaheim, California + 39 more",
      "locations": [
        {
          "city": "Bentonville",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Bellflower",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04103892"
    },
    {
      "nct_id": "NCT04261387",
      "title": "LUT014 for the Treatment of Radiation Induced Dermatitis in Breast Cancer Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Radiation Dermatitis"
      ],
      "interventions": [
        {
          "name": "LUT014 Gel",
          "type": "DRUG"
        },
        {
          "name": "Placebo for LUT014 Gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lutris Pharma Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 28,
      "start_date": "2021-01-30",
      "completion_date": "2022-07-15",
      "has_results": false,
      "last_update_posted_date": "2022-07-27",
      "last_synced_at": "2026-09-18T21:55:33.940Z",
      "location_count": 2,
      "location_summary": "Columbus, Georgia • Shreveport, Louisiana",
      "locations": [
        {
          "city": "Columbus",
          "state": "Georgia"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04261387"
    },
    {
      "nct_id": "NCT01947738",
      "title": "Safety Study of VBY-891 in Healthy Volunteers After Single or Multiple (7 Days) of Oral Dosing (VBY891P1)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "VBY-891",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Virobay Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 89,
      "start_date": "2013-03",
      "completion_date": "2013-05",
      "has_results": false,
      "last_update_posted_date": "2013-12-31",
      "last_synced_at": "2026-09-18T21:55:33.940Z",
      "location_count": 1,
      "location_summary": "Evansville, Indiana",
      "locations": [
        {
          "city": "Evansville",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01947738"
    },
    {
      "nct_id": "NCT02500147",
      "title": "Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Polycystic Ovary Syndrome",
        "Non-Alcoholic Fatty Liver Disease",
        "Metabolic Syndrome"
      ],
      "interventions": [
        {
          "name": "Metformin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "25 Years",
        "sex": "FEMALE",
        "summary": "13 Years to 25 Years · Female only"
      },
      "enrollment_count": 3,
      "start_date": "2011-09-08",
      "completion_date": "2021-03-03",
      "has_results": true,
      "last_update_posted_date": "2025-07-02",
      "last_synced_at": "2026-09-18T21:55:33.940Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02500147"
    },
    {
      "nct_id": "NCT07220811",
      "title": "Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ig-E Mediated Food Allergy"
      ],
      "interventions": [
        {
          "name": "RPT904",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "RAPT Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "12 Years to 55 Years"
      },
      "enrollment_count": 100,
      "start_date": "2025-10-22",
      "completion_date": "2028-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-28",
      "last_synced_at": "2026-09-18T21:55:33.940Z",
      "location_count": 22,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Palo Alto, California + 18 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07220811"
    }
  ]
}